Erythropoietic response after IV iron in patients with HFrEF with and without background treatment with SGLT2 inhibitors.

Combined treatment with IV iron and background SGLT2i was associated with a greater increase in hemoglobin and hematocrit than IV iron without background SGLT2i. These results suggest that in HFrEF patients treated with IV iron, SGLT2i may increase the erythropoietic response. Further studies are needed to ascertain the potential benefit or harm of combining these two treatments in HF patients. This article is protected by copyright. All rights reserved.